ATR Inhibitors in Platinum-Resistant Ovarian Cancer

Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including t...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-11, Vol.14 (23), p.5902
Main Authors: Li, Siyu, Wang, Tao, Fei, Xichang, Zhang, Mingjun
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Ataxia telangiectasia
Ataxia telangiectasia mutated protein
Bevacizumab
Cancer therapies
Cell cycle
Chemical inhibitors
Chemotherapy
Clinical trials
Collaboration
Disease
DNA damage
Dosage and administration
Drug delivery
Drug therapy
Gene expression
Homologous recombination
Immunotherapy
Kinases
Medical prognosis
Mutation
Ovarian cancer
Palliative care
Patients
Platinum
Prognosis
Protein kinase inhibitors
Proteins
Radiation therapy
Response rates
Review
Ribose
Surgery
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14235902